Nola Masterson, Director. Ms. Masterson has served on the Board of Directors at Omicia since May 2003 and is the managing director of Science Futures LLC, a Private Equity Fund. She has more than 32 years of business experience in the life sciences and venture capital investment. Early in her career Ms. Masterson held various senior management positions at Ames Corp, a Bayer Corporation, and Millipore Corporation. In 1983, she founded Science Futures, Inc., a financial and advisory service company supporting the biotechnology public markets in the US and Europe. In 1993, she co-founded Sequenom (NASDAQ: SQNM), one of the pioneering genomics companies, and served on its board of directors until 1998. Ms. Masterson was responsible for opening the San Francisco offices of the venture capital firm TVM-Capital. She founded the Biopharmaceutical Conference in Europe and the Biotech Meeting at Laguna Niguel, California, both of which foster alliances between pharmaceutical and emerging life science companies. Ms. Masterson chairs the BayBio Institute and serves on the boards of Generex (NASDAQ: GNBT), Repros Therapeutics (NASDAQ: RPRX), Astia, and the Professional Women's Healthcare Alliance. She holds a MSc. in biological sciences from George Washington University.

Martin G. Reese, Ph.D., CEO, President, and Co-Founder. Dr. Reese is a serial entrepreneur and a recognized expert in the field of bioinformatics. In 1996, he co-founded Neomorphic, Inc., in Berkeley, CA. As Neomorphic's President and Chief Scientific Officer, he was instrumental in developing their genome annotation software. Dr. Reese brought Neomorphic from its beginnings as a spinout from academia, through profitable licensing of its software and databases from UC Berkeley, to the sale of the company to Affymetrix (NASDAQ: AFFX) in 2000. Dr. Reese also served as Vice President of Discovery Informatics for ValiGen N.V., a Euro-American biotechnology company, from 2000 to 2002, where he was in charge of integrating three business units consisting of functional genomics, gene targeting and population genetics. In parallel with his industry appointment at Neomorphic, Dr. Reese was a member of the Berkeley Drosophila Genome Project (BDGP) led by Dr. Gerald Rubin, which provided the preliminary run for the technology co-developed by Celera for sequencing the human genome. During his time at the BDGP, Dr. Reese developed novel algorithms for gene finding, promoter and splice site prediction, which subsequently was used for the annotation of the Drosophila and human genomes. In 1999, he organized the Genome Annotation Assessment Project (GASP), a community-wide objective assessment in state-of-the-art genome annotation using the Drosophila genome. He was also an advisor to the EGASP project in 2005, a successful follow-on to GASP funded by the NIH-sponsored ENCODE project. Dr. Reese holds an MS in medical informatics from the University of Heidelberg and a Ph.D. in genetics from the University of California, Berkeley/University of Hohenheim, Germany.

Isaac Cohen, O.M.D., L.Ac., Director. Dr. Cohen is the Chairman, Chief Executive Officer and Co-Founder of Bionovo Inc (NASDAQ: BNVI), a pharmaceutical company focusing on discovery and development of drugs for women's health and cancer. He is also a Guest Scientist at the University of California, San Francisco and has been involved with the UCSF Cancer Research Center and UCSF Center for Reproductive Endocrinology for the past twelve years. He is one of the founding members of the University of California, San Francisco Carol Franc Buck Breast Care Center Complementary and Alternative Medicine Research Program. He is a co-investigator on numerous basic and clinical grants and has assembled teams of scientists from four different universities to work on his projects. Dr. Cohen graduated from the Pacific College of Oriental Medicine in San Diego and he completed his doctorate degree at the Postgraduate Institute of Oriental Medicine in Hong Kong, China. His expertise is in translational science, and working from the bench to the clinic, he has developed a number of products for clinical testing that have been awarded an FDA IND, as well as a pipeline of over 50 candidate drugs.

Charles White, Chairman and Co-Founder. Mr. White is the President and co-founder of EmergentViews, Inc, an imaging systems company. He is a serial entrepreneur who has founded and held executive positions in a diverse set of startup companies. He was the CEO of HomeAccount, a venture-backed Internet banking services company, until its sale to Intelidata. Previously, Mr. White was President of Transpoint, a joint venture between Microsoft and First Data Corporation that was later sold to Checkfree Corporation. He was also a board member at Neomorphic, Inc., a bioinformatics company acquired by Affymetrix Corporation (NASDAQ: AFFX). He currently serves as Chairman of the board of Aequitas Innovation, Inc., a company focused on delivering products and services that eliminate theft in the supply chain. Mr. White holds a BS in Computer Science from the University of Florida, and an MBA from the University of California, Berkeley.